Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive cenobamate for primary generalized tonic-clonic seizures
2018-001337-41Phase 3Active
- Sponsor
- SK Life Science, Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized tonic-clonic seizure (GTCS) comparing Cenobamate adjunctive therapy with Placebo adjunctive therapy (2 arms). Started Oct 2018; status: active.
02
Drugs
cenobamate
03
Conditions
generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2018-001337-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001337-41.